MolDX: Molecular Testing for Identification and Management of Hereditary Transthyretin Amyloidosis

Genetic testing for suspected hereditary transthyretin amyloidosis (hATTR) is covered when patients meet clinical criteria (clinical ATTR diagnosis, cardiac features with supporting elements, or progressive sensorimotor/autonomic neuropathy with supporting elements), have been offered pre‑test counseling, and results will inform treatment. Covered tests must include guideline‑based minimum genetic content, avoid additional potentially harmful content, may be single‑variant only if it is a known familial variant, and must have successfully completed a technical assessment (TA).

"Molecular testing is covered for patients with a clinical diagnosis of ATTR (suspected hereditary transthyretin amyloidosis)."

Sign up to see full coverage criteria, indications, and limitations.